Business context and reporting period
The filing is Bio Blast Pharma Ltd.’s audited Form 20-F for the fiscal year ended December 31, 2014—not a standalone fourth-quarter report. The request metadata names Enlivex Ltd.; that does not match the registrant named in the filing. Bio Blast was an Israeli development-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic and metabolic diseases. Its ordinary shares traded on Nasdaq under ORPN after its July 2014 IPO.
Key financial metrics
| Metric | FY 2014 / Dec. 31, 2014 | Prior comparable period |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $4.441 million | $0.732 million in 2013 |
| General and administrative expense | $2.639 million | $0.416 million in 2013 |
| Operating loss | $7.080 million | $1.148 million in 2013 |
| Net loss attributable to ordinary shareholders | $7.022 million; $0.57 per share | $1.171 million; $0.14 per share in 2013 |
| Cash used in operating activities | $4.409 million | $0.865 million in 2013 |
| Cash and cash equivalents | $10.583 million | $0.270 million |
| Short-term bank deposits | $22.028 million | None reported |
| Working capital | $30.605 million | $0.168 million |
| Total assets / shareholders’ equity | $32.954 million / $30.674 million | $0.306 million / $0.175 million |
Amounts are in U.S. dollars. Cash, cash equivalents and short-term deposits totaled $32.611 million. Current liabilities were $2.280 million. The balance sheet reports no interest-bearing debt; liabilities shown are trade and other payables. Margins are not meaningful because the company had no product revenue.
Material changes versus the prior period
- Operating expenses increased sharply as clinical and preclinical development expanded. R&D rose 507% and G&A rose 534% year over year, as reported by the company.
- The net loss increased to $7.022 million from $1.145 million. R&D spending was led by OPMD and SMA programs; higher G&A also reflected public-company costs, staffing, facilities and share-based compensation.
- The August 2014 IPO raised approximately $31.4 million net. Including other share issuances, financing activities provided $36.785 million in 2014. The company invested $22.0 million in short-term bank deposits.
- Ordinary shares outstanding increased to 14,230,480 from 9,182,867 at year-end 2013.
Outlook, risks and unusual items
- Management estimated that available cash and short-term deposits would fund current plans until the end of 2016 or early 2017, but expected to need substantial additional capital for regulatory approval and commercialization. Funding needs depend on trial scope, progress, manufacturing, and other costs; financing may not be available on acceptable terms.
- The company expected rising R&D expense and operating losses and did not expect product-sale revenue in the next few years. It had no approved products and had incurred losses since inception.
- Pipeline status included Cabaletta (trehalose) in Phase 2/3 for OPMD and Phase 2 for SCA3; other candidates were in preclinical development. The filing described plans for further studies, subject to results and regulatory approvals, not assured milestones.
- Key risks include clinical failure or delay, limited rare-disease patient pools, adverse effects, regulatory uncertainty, dependence on third-party CROs and single-source manufacturing for some candidates, uncertain intellectual-property protection, competition, reimbursement and pricing, and dependence on future financing.
- Other exposures include NIS/U.S. dollar movements (about 23% of 2014 expenses were NIS-denominated; the company did not hedge), Israeli political and security conditions, and possible passive foreign investment company (PFIC) status for U.S. investors.
- Unusual financing and compensation items included the IPO, share-based compensation of $0.736 million, and $170,000 of special IPO-related bonuses to related-party service providers. The filing also reported related-party expenses and license royalty and sublicense obligations.
- The auditor issued an unqualified opinion on the financial statements. Management said disclosure controls were effective; the filing did not include management’s assessment or the auditor’s attestation on internal control over financial reporting, citing applicable transition exemptions.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied metadata says Enlivex Ltd., while the filing is for Bio Blast Pharma Ltd.
- Review the complete audited statements and notes, including cash-deposit maturity and accessibility, payables, license commitments, lease obligations, and related-party transactions.
- Check subsequent clinical, regulatory and financing developments against the filing’s plans and runway estimate; those statements were forward-looking and conditional.
- Verify current share count, option dilution, ownership concentration, and trading status; year-end 2014 figures and March 2015 ownership disclosures may no longer reflect current conditions.
- U.S. investors should independently assess PFIC status and related tax implications with a tax adviser.